Mobocertinib price

Mobocertinib, also known as TAK-788, is a drug used to treat non-small cell lung cancer (NSCLC). Specifically, mobosetinib is a tyrosine kinase inhibitor used to treat patients with EGFR (epidermal growth factor receptor) mutation-positive NSCLC.

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug, and the ingredients of the original drug and the generic drug are the same.

EGFRmutation is a common NSCLC driver mutation. Mobosetinib prevents the growth and division of tumor cells by inhibiting EGFRkinase activity. The drug was developed to target patients who have developed resistance to other EGFR inhibitors, particularly those who carry the EGFR T790M mutation.

Mobosetinib has shown potential in clinical trials as a treatment option for EGFRmutation-positiveNSCLC. However, drug use and availability may vary by region and health care policy. Patients should consult their healthcare professional for advice and information about whether moboxetinib is appropriate for their specific situation.